コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
1 Serious adverse events occurred in 3 patients.
2 Overall, 36
serious adverse events occurred in 21 (28%) patients.
3 Serious adverse events occurred in 16 placebo patients (
16%)
4 Serious adverse events occurred in 4 patients (
2 in the FMT g
5 Serious adverse events occurred in ten patients (
32%) and wer
6 Serious adverse events occurred in 19 patients (
33%) in the s
7 Serious adverse events occurred in 72 patients (
34%) in the i
8 Serious adverse events occurred in 23% of patients (
35 of 154
9 Serious adverse events occurred in 92 patients (
37%) in the c
10 Serious adverse events occurred in 74 patients (
38%) in the o
11 A total of 38
serious adverse events occurred in 15 patients (
5 events were
12 Serious adverse events occurred in 72 patients (
8.4%), report
13 Serious adverse events occurred in six patients,
and in six p
14 Serious adverse events occurred in two (2%) patients each in
15 Serious adverse events occurred in 12% of patients given adal
16 No
serious adverse events occurred in patients given ISIS 333611
17 Serious adverse events occurred in three patients;
however, t
18 Serious adverse events occurred in 12 (6%) patients in the tr
19 Serious adverse events occurred in 14 patients in the azathio
20 Serious adverse events occurred in 18 patients in the placebo
21 Serious adverse events occurred in 2 patients in the IFN grou
22 Drug-related
serious adverse events occurred in 39 (10%) patients in the a
23 Serious adverse events occurred in 53% of patients in the pla
24 Serious adverse events occurred in 6% of patients in the cont
25 Serious adverse events occurred in 75 (19%) patients in the c
26 Serious adverse events occurred in 84 (25%) patients in the f
27 Serious adverse events occurred in 88 patients in the enalapr
28 Serious adverse events occurred in four patients in each grou
29 Treatment-related
serious adverse events occurred in two patients in the inflix
30 12
serious adverse events occurred in six patients,
including on
31 Serious adverse events occurred in 59 (55%) patients, irrespe
32 37
serious adverse events occurred in patients receiving rituxim
33 Serious adverse events occurred in seven patients receiving m
34 Serious adverse events occurred in eight (62%) patients; thro
35 Serious adverse events occurred in 51% of patients undergoing
36 Serious adverse events occurred in 19% of patients who receiv
37 Serious adverse events occurred in 4% of patients who receive
38 Serious adverse events occurred in five (8%) patients who rec
39 Serious adverse events occurred in 18 (17%) patients,
with th
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。